Related Experiment Video
Updated: Feb 11, 2026

A Novel Method for Involving Women of Color at High Risk for Preterm Birth in Research Priority Setting
Published on: January 12, 2018
Rationale for current and future progestin-based therapies to prevent preterm birth
Megan Weatherborn1, Sam Mesiano2
1Department of Obstetrics and Gynecology, University Hospitals of Cleveland, Cleveland, OH, USA.
Insights
Progestin therapy, including micronized progesterone, helps prevent preterm birth (PTB) in high-risk women. New research explores progesterone signaling pathways to improve PTB prevention for more pregnancies.
Area of Science:
- Reproductive biology
- Maternal-fetal medicine
- Pharmacology
Background:
- Preterm birth (PTB) is a major global cause of newborn illness and death.
- Current therapies like micronized progesterone and 17α-hydroxyprogesterone caproate reduce PTB risk in specific high-risk groups.
- The exact mechanisms by which progestins prevent PTB are not fully understood.
Purpose of the Study:
- To investigate the molecular mechanisms of progesterone (P4) signaling in uterine cells.
- To identify novel therapeutic targets for improving PTB prevention strategies.
- To enhance the effectiveness of progestin therapy for a broader range of pregnancies.
Main Methods:
- Analysis of P4 signaling pathways via P4 receptor isoforms in uterine cells.
- Exploration of molecular biology and physiology related to progesterone action.
- Focus on pathways involved in inflammation-induced parturition.
Main Results:
- Advances in understanding P4 signaling pathways have been achieved.
- Novel therapeutic targets for PTB prevention have been identified.
- Potential for improving progestin therapy effectiveness is suggested.
Conclusions:
- Understanding P4 signaling offers new avenues for PTB prevention.
- Targeting key steps in inflammation-induced parturition may enhance therapy.
- Future strategies could improve PTB prevention for the majority of pregnancies.
Abstract:
Preterm birth (PTB) is the leading cause of neonatal morbidity and mortality worldwide. The only medicinal therapy currently recommended to prevent PTB is prophylactic progestin therapy in the form of micronized progesterone (P4) administered daily via vaginal suppository from the 24th to the 34th week of gestation or 17α-hydroxyprogesterone caproate in oil administered weekly from the 16th to the 36th week of gestation via an intramuscular injection. These therapies decrease the risk of PTB in women with an elevated risk of PTB indicated by a history of PTB or by a short cervix measured by sonography at mid-gestation. The mechanism by which progestin therapy prevents PTB in some women is not clear but may involve non-progestin mechanism and/or supplementation of localized progestin deficiency. Advances in understanding the molecular biology and physiology of P4 signaling via the P4 receptor isoforms in uterine cells reveal novel therapeutic targets; this may improve the effectiveness of progestin therapy to prevent PTB in the majority of pregnancies by targeting key steps in the pathway leading to inflammation-induced parturition.
Related Concept Videos
Birth Control Methods
Urinary Tract Calculi IV: Nutrition Therapy and Prevention
Gene Therapy
Cancer Prevention
Some...
Prevention of Further Absorption of Poison
Preventive Healthcare Services

